You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Preclinical development of novel small molecule malaria drugs that overcome drug

    SBC: DESIGNMEDIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. This project initiates preclinical development of one or more candidate(s) from an innovative newclass of potent antimalarials designed to overcome drug resistance. We have developed an orally available and inexpensive class of novel drugs th ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. A vaccine against Clostridium difficile infections

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): In this proposal we lay out a comprehensive research plan to evaluate our vaccination strategies targeting Clostridium difficile to prevent or treat infections. With the emergence of highly antibiotic-resistant bacterial strains, new approaches for combating bacterial infections are desperately needed. In this research proposal, Sorrento Therapeutics Inc. (STI ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Liposomal Nicotine Vaccine Development

    SBC: MOLECULAR EXPRESS, INC            Topic: NIDA

    DESCRIPTION (provided by applicant): In response to RFA-DA-11-004, we propose in this STTR Phase I application to develop and test a nicotine vaccine utilizing a chemical derivative of the drug, or hapten, coupled to an immunostimulatory, adjuvant-containing liposome. The current approach to curbing nicotine addiction is the use of over the counter nicotine replacement products, but this approach ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. In vivo and in vitro tools to target CHRNA5 for smoking cessation.

    SBC: OPHIDION, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Nicotine is one of the most heavily used addictive drugs and accounts for 90% of lung cancer cases in the U.S. Recent studies have implicated a specialized receptor class binding to nicotine, the CHRNA5 gene, which encodes the a5 subunit of the nicotinic receptor, as a contributing factor in the risk towards nicotine dependence. This, along with animal studies ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. FAH-Deficient Pigs

    SBC: Yecuris Corporation            Topic: NIDDK

    DESCRIPTION (provided by applicant): Translational research in the field of liver disease has been limited by a shortage of large animal models, which in turn has limited development of new therapies for metabolic liver disorders, acute liver failure, chronic (cirrhotic) liver disease, an hepatocellular carcinoma. While new transgenic and knockout rodent models of liver disease have facilitated ba ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Injury-targeted decorin for systemic anti-fibrotic treatment

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): The repair of injuries is dominated by a tendency to re-establish tissue continuity rather than restoring the structure of the original tissue. This process results in scarring and fibrosis, which is a major medical problem spanning diseases in all organ systems. This application focuses on a compound that has been shown to be highly effective in reducing scarr ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Azaborine Derivatives Predicted to Eliminate Acetaminophen Hepatotoxicity

    SBC: QUINTESSENCE CHEMICALS, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Overdose on acetaminophen (more commonly known by the brand name Tylenol(R)), accounts for 56,000 emergency room visits and more than 450 deaths annually in the USA. Acetaminophen overdose can occur by a single event ofexceeding the recommended daily dosage. Overdose on acetaminophen is facilitated by the fact that it is a common ingredient in over-the-counter ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. An Acoustic Respiratory Movement Sensor (ARMS) to Produce and Monitor SIMV in Inf

    SBC: BIODATA INNOVATION SYSTEMS, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): This project will demonstrate the feasibility of the use of non-contacting acoustic respiratory movement sensor (ARMS) for a device that will be used as a sensor for a module that can trigger any commercially availableneonatal ventilator to produce non-invasive synchronized ventilation. Synchronization of the ventilator improves gas exchange, decreases the leng ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Effects of OX2R agonist and antagonist on sleep apnea

    SBC: BIOFUNC RESEARCH            Topic: NHLBI

    DESCRIPTION (provided by applicant): The long term goal of this project is to develop and commercialize a drug to treat sleep apnea. Sleep apnea is a common medical condition and associated with excessive daytime sleepiness and is a composite risk for cardiovascular morbidity and mortality. Presently, there are no effective pharmacotherapies for individuals with sleep apnea. Growing evidence from ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Medicinal Chemicals: Cardiomyogenesis from Human Stem Cells

    SBC: ChemRegen Inc            Topic: NHLBI

    DESCRIPTION (provided by applicant): Over 1-2% of Americans greater than 65 years of age have heart disease. According to the American Heart Association, heart failure is one of the most common causes of hospitalization for patients over 65 years of age inthe Western world and as the population ages, this situation will only get worse. Currently, more than 5 million Americans suffer from heart fai ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government